What is HC Wainwright’s Estimate for AQST Q1 Earnings?

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Aquestive Therapeutics in a research note issued on Monday, March 10th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings of ($0.17) per share for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Aquestive Therapeutics’ Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.15) EPS and FY2025 earnings at ($0.61) EPS.

A number of other analysts have also issued reports on the company. Alliance Global Partners reaffirmed a “buy” rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Raymond James set a $7.00 price objective on Aquestive Therapeutics in a research note on Friday, March 7th. Cantor Fitzgerald began coverage on Aquestive Therapeutics in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 target price on the stock. Finally, Lake Street Capital decreased their price target on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, March 7th. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $10.57.

Aquestive Therapeutics Price Performance

Shares of AQST stock opened at $2.94 on Wednesday. The company’s fifty day moving average price is $3.04 and its two-hundred day moving average price is $4.07. The firm has a market capitalization of $290.68 million, a P/E ratio of -6.53 and a beta of 2.76. Aquestive Therapeutics has a 12 month low of $2.24 and a 12 month high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last posted its earnings results on Wednesday, March 5th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The firm had revenue of $11.87 million for the quarter, compared to analyst estimates of $13.11 million.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of AQST. Vanguard Group Inc. increased its holdings in shares of Aquestive Therapeutics by 1.9% in the 4th quarter. Vanguard Group Inc. now owns 4,346,754 shares of the company’s stock valued at $15,474,000 after acquiring an additional 82,958 shares during the last quarter. Geode Capital Management LLC increased its stake in Aquestive Therapeutics by 5.7% during the third quarter. Geode Capital Management LLC now owns 1,667,515 shares of the company’s stock valued at $8,306,000 after purchasing an additional 90,543 shares during the last quarter. State Street Corp raised its holdings in shares of Aquestive Therapeutics by 52.1% during the third quarter. State Street Corp now owns 1,496,739 shares of the company’s stock worth $7,454,000 after purchasing an additional 512,682 shares during the period. Janney Montgomery Scott LLC lifted its position in shares of Aquestive Therapeutics by 6.6% in the 4th quarter. Janney Montgomery Scott LLC now owns 984,485 shares of the company’s stock worth $3,505,000 after buying an additional 61,200 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in shares of Aquestive Therapeutics by 905.2% in the 4th quarter. Bank of America Corp DE now owns 690,284 shares of the company’s stock worth $2,457,000 after buying an additional 621,614 shares during the last quarter. Institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.